Novo Nordisk and OpenAI Establish Strategic Partnership

Global pharmaceutical giant Novo Nordisk today announced a global strategic partnership with OpenAI. The two companies will integrate cutting-edge large-scale modeling technology and biopharmaceutical resources, focusing on three key areas: drug development, manufacturing operations, and employee empowerment. They will leverage OpenAI models to deeply mine medical data, accelerating target discovery, candidate drug screening, and clinical trial design, thereby shortening the time to market for new drugs.